Edition:
United States

GlaxoSmithKline PLC (GSK.N)

GSK.N on New York Stock Exchange

40.34USD
16 Nov 2018
Change (% chg)

$-0.07 (-0.17%)
Prev Close
$40.41
Open
$40.10
Day's High
$40.53
Day's Low
$40.07
Volume
805,278
Avg. Vol
577,669
52-wk High
$42.36
52-wk Low
$34.52

Chart for

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 0.76
Market Cap(Mil.): $100,652.80
Shares Outstanding(Mil.): 2,480.28
Dividend: 0.49
Yield (%): 5.17

Financials

  GSK.N Industry Sector
P/E (TTM): 26.87 28.12 29.34
EPS (TTM): 1.54 -- --
ROI: 10.07 14.10 13.58
ROE: 101.91 15.67 15.11

GSK feels shingles vaccine boost, but shares slip on drugs mix

LONDON GlaxoSmithKline's third-quarter earnings were lifted by demand for its new shingles vaccine on Wednesday, but the British drugs firm's shares slipped despite an improved outlook as analysts focused on some drugs missing forecasts.

Oct 31 2018

UPDATE 3-GSK feels shingles vaccine boost, but shares slip on drugs mix

* Shares reverse gains to trade down 2 pct (Adds further quotes on drug pipeline, updates shares)

Oct 31 2018

GSK beats Q3 forecasts on strong Shingrix sales, nudges up guidance

LONDON, Oct 31 Pharmaceutical firm GlaxoSmithKline beat expectations with a 3 percent rise in third-quarter sales and a 10 percent rise in earnings per share on Wednesday thanks in part to strong demand for its new shingles vaccine Shingrix.

Oct 31 2018

UK Stocks-Factors to watch on Oct 31

Oct 31 Britain's FTSE 100 index is seen opening 48 points higher at 7,084 on Wednesday, according to financial bookmakers. * STANDARD CHARTERED: Standard Chartered reported on Wednesday a better than expected 31.3 percent rise in quarterly profit before tax, as the British lender attempts to bring down stubbornly high costs and boost flatlining revenues. * RANDGOLD RESOURCES: Randgold Resources Ltd said on Tuesday its Loulo-Gounkoto gold mining complex in Mali had s

Oct 31 2018

Long-lasting HIV injection is a step closer after second GSK study

LONDON A once-monthly injection to control HIV proved as effective as daily pills in a second study by GlaxoSmithKline, paving the way for a new regimen that could be simpler for some patients to be filed with regulators.

Oct 30 2018

Long-lasting HIV injection is a step closer after second GSK study

LONDON, Oct 30 A once-monthly injection to control HIV proved as effective as daily pills in a second study by GlaxoSmithKline, paving the way for a new regimen that could be simpler for some patients to be filed with regulators.

Oct 30 2018

Kraft Heinz to sell part of India business for about $630 million

Kraft Heinz Co will sell part of its Indian business, including brands such as malt-based drink Complan and energy drink Glucon-D, for 45.95 billion rupees ($627.18 million), at a time when Indian consumers are demanding healthier, sugar-free alternatives.

Oct 24 2018

UPDATE 2-Kraft Heinz to sell part of India business for about $630 mln

* Deal does not assume any debt (Recasts throughout to add background, deal details)

Oct 24 2018

Ex-GSK scientist's sister admits to role in trade secret theft scheme

The sister of a former GlaxoSmithKline Plc researcher pleaded guilty on Monday to helping hide the proceeds of what U.S. prosecutors say was a scheme to steal trade secrets related to drugs the British pharmaceutical company was developing.

Oct 22 2018

Stada, buyout funds in race for Bristol-Myers' French business: sources

LONDON German generic drugmaker Stada is vying with a group of European buyout funds for control of Bristol-Myers Squibb's French over-the-counter drugs business, sources familiar with the matter told Reuters.

Oct 08 2018

Earnings vs. Estimates